To see the other types of publications on this topic, follow the link: Addictovigilance.

Journal articles on the topic 'Addictovigilance'

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Addictovigilance.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Jouanjus, Emilie, Joëlle Micallef, Michel Mallaret, and Maryse Lapeyre-Mestre. "Comment on: An Insight Into Z-Drug Abuse and Dependence: An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions." International Journal of Neuropsychopharmacology 22, no. 8 (2019): 528–30. http://dx.doi.org/10.1093/ijnp/pyz033.

Full text
Abstract:
Abstract After the publication of an article discussing the methodological options to detect the diversion potential of prescription drugs, this letter presents the multidimensional functioning of the French Addictovigilance System. This system aims at monitoring all substances with abuse potential, relying on a network of experts specialized in clinical and fundamental pharmacology. For more than 25 years, we have created collaborations with partners at the interface with field data related to substance use and the potential related disorders. When relevant depending on the context, these dat
APA, Harvard, Vancouver, ISO, and other styles
2

Chavant, François, Alexandra Boucher, Reynald Le Boisselier, Sylvie Deheul, and Danièle Debruyne. "New Synthetic Drugs in Addictovigilance." Therapies 70, no. 2 (2015): 179–89. http://dx.doi.org/10.2515/therapie/2015001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Chavant, François, Alexandra Boucher, Reynald Le Boisselier, Sylvie Deheul, and Danièle Debruyne. "Nouvelles drogues de synthèse en addictovigilance." Therapies 70, no. 2 (2015): 167–78. http://dx.doi.org/10.2515/therapie/2014235.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Jouanjus, Emilie, Valérie Gibaja, Jean-Pierre Kahn, Françoise Haramburu, and Amélie Daveluy. "Comment identifier un signal en addictovigilance ?" Therapies 70, no. 2 (2015): 113–22. http://dx.doi.org/10.2515/therapie/2015009.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Daveluy, Amélie, Joëlle Perri-Plandé, Marie Baumevieille, Alexandre Peyré, and Ghada Miremont-Salamé. "Addictovigilance dans les départements d’Outre-Mer." Therapies 73, no. 6 (2018): 565. http://dx.doi.org/10.1016/j.therap.2018.09.062.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Gibaja, Valérie, Audrey Fresse, Juliana Tournebize, and Maryse Lapeyre Mestre. "Poudre d’opium et addictovigilance : état des lieux." Therapies 76, no. 2 (2021): 164. http://dx.doi.org/10.1016/j.therap.2021.01.015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gentile, Gaétan, Maeva Jego, Michel Spadari, Karolina Griffiths, Emilie Jouanjus, and Joëlle Micallef. "Identification and tracking of Addictovigilance signals in general practice: which interactions between the general practitioners and the French Addictovigilance Network?" Fundamental & Clinical Pharmacology 32, no. 6 (2018): 643–51. http://dx.doi.org/10.1111/fcp.12401.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Lapeyre-Mestre, Maryse. "Identification and tracking of addictovigilance signals in general practice: which interactions between the general practitioners and the French addictovigilance network?" Fundamental & Clinical Pharmacology 32, no. 6 (2018): 641–42. http://dx.doi.org/10.1111/fcp.12425.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Jouanjus, Emilie, Valérie Gibaja, Jean-Pierre Kahn, Françoise Haramburu, and Amélie Daveluy. "Signal Identification in Addictovigilance: the Functioning of the French System." Therapies 70, no. 2 (2015): 123–31. http://dx.doi.org/10.2515/therapie/2015011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Batisse, A., C. Eiden, R. Le Boisselier, et al. "New psychoactive substances: French addictovigilance data between 2009 and 2017." Toxicologie Analytique et Clinique 31, no. 2 (2019): S42—S43. http://dx.doi.org/10.1016/j.toxac.2019.03.057.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Lapeyre-Mestre, Maryse, Alexandra Boucher, Amélie Daveluy, et al. "Addictovigilance contribution during COVID-19 epidemic and lockdown in France." Therapies 75, no. 4 (2020): 343–54. http://dx.doi.org/10.1016/j.therap.2020.06.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Marillier, M., A. Batisse, C. Chevallier, and S. Djezzar. "Behavioral disorders and new psychoactive substances abuse, a French case series." European Psychiatry 33, S1 (2016): S307. http://dx.doi.org/10.1016/j.eurpsy.2016.01.1050.

Full text
Abstract:
IntroductionRange of drugs has largely increased the past few years, especially with the emergence of the New Psychoactive Substances (NPS) sold online. In front of serious risks they cause on human health, they are more and more regulated by the law.ObjectivesTo describe cases of extreme behavioral disorders and highlight risks of potential forensic complications linked to these consumptions.MethodsWe present a case series of serious auto or hetero-aggressive behavioral disorders related to NPS abuse and notified to the Parisian addictovigilance center.ResultsTwenty cases were identified betw
APA, Harvard, Vancouver, ISO, and other styles
13

Eiden, Céline, Sarah Leone-Burgos, Anaïs Serre, et al. "Ephenidine, diphenidine, and methoxphenidine complications reported to the French Addictovigilance Network." Fundamental & Clinical Pharmacology 32, no. 6 (2018): 654–62. http://dx.doi.org/10.1111/fcp.12395.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Rousselet, Morgane, Fanny Feuillet, Marie Gerardin, Pascale Jolliet, Jean-Benoit Hardouin, and Caroline Victorri-Vigneau. "The French addictovigilance network clinical assessment: Z-drugs, true false twins." Expert Opinion on Drug Safety 16, no. 9 (2017): 1063–69. http://dx.doi.org/10.1080/14740338.2017.1346084.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Lapeyre-Mestre, Maryse, and Mathilde Dupui. "Système de surveillance en addictovigilance : quelles données pharmacoépidémiologiques à l'échelle de l'Europe ?" Therapies 70, no. 2 (2015): 147–56. http://dx.doi.org/10.2515/therapie/2015006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Micallef, Joëlle, Elisabeth Frauger, Aurore Palmaro, Quentin Boucherie, and Maryse Lapeyre Mestre. "Un exemple d’investigation d’un phénomène « émergent » en addictovigilance : à propos du méthylphénidate." Therapies 70, no. 2 (2015): 191–96. http://dx.doi.org/10.2515/therapie/2015012.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Victorri-Vigneau, Caroline, Jean Benoit Hardouin, Morgane Rousselet, et al. "Multicentre study for validation of the French addictovigilance network reports assessment tool." British Journal of Clinical Pharmacology 82, no. 4 (2016): 1030–39. http://dx.doi.org/10.1111/bcp.13044.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Batisse, Anne, Juliana Tournebize, Julie Heredia, Leila Chaouachi, Samira Djezzar, and Le Boisselier Reynald. "AddictoVigilance sur le mode de consommation par vapotage de substances psychoactives illicites." Toxicologie Analytique et Clinique 32, no. 4 (2020): S18—S19. http://dx.doi.org/10.1016/j.toxac.2020.09.043.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Micallef, Joëlle, and Michel Mallaret. "Les 25 ans des centres d’évaluation et d’information sur la pharmacodépendance-addictovigilance." Therapies 71, no. 4 (2016): 375–78. http://dx.doi.org/10.1016/j.therap.2016.05.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Micallef, Joëlle, and Maryse Lapeyre-Mestre. "Addictovigilance : le défi pharmacologique de l’évaluation et de la prévention des substances à risque." Therapies 70, no. 2 (2015): 111. http://dx.doi.org/10.2515/therapie/2015017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Roussin, Anne, Odile Doazan d’Ouince, Hélène Géniaux, and Clémence Halberer. "Un exemple d’évaluation de l’abus et de la dépendance en addictovigilance : à propos du tramadol." Therapies 70, no. 2 (2015): 203–11. http://dx.doi.org/10.2515/therapie/2014221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Micallef, J. "Nouveaux produits de synthèse (NPS) et addictovigilance : de la pharmacodynamie théorique aux complications somatiques réelles." Toxicologie Analytique et Clinique 30, no. 2 (2018): S44—S45. http://dx.doi.org/10.1016/j.toxac.2018.04.053.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Vodovar, Dominique, and Bruno Megarbane. "Ephenidine, diphenidine and methoxphenidine complications reported to the French Addictovigilance Network: another brick in the wall!" Fundamental & Clinical Pharmacology 32, no. 6 (2018): 652–53. http://dx.doi.org/10.1111/fcp.12407.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Dupui, Mathilde, Joëlle Micallef, and Maryse Lapeyre-Mestre. "Interest of large electronic health care databases in addictovigilance: Lessons from 15 years of pharmacoepidemiological contribution." Therapies 74, no. 2 (2019): 307–14. http://dx.doi.org/10.1016/j.therap.2018.09.078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Schreck, Benoît, Nicolas Wagneur, Pascal Caillet, et al. "Cannabinoid hyperemesis syndrome: Review of the literature and of cases reported to the French addictovigilance network." Drug and Alcohol Dependence 182 (January 2018): 27–32. http://dx.doi.org/10.1016/j.drugalcdep.2017.09.038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Micallef, Joëlle, and Michel Mallaret. "Assessment of new psychoactive substances: Opportunities for more interactions between analytical toxicologists and the French Addictovigilance Network." Toxicologie Analytique et Clinique 31, no. 4 (2019): 195–96. http://dx.doi.org/10.1016/j.toxac.2019.07.003.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Peyrière, Hélène, Céline Eiden, Michel Mallaret, and Caroline Victorri-Vigneau. "Medical complications of psychoactive substances with abuse risks: Detection and assessment by the network of French addictovigilance centres." Therapies 71, no. 6 (2016): 563–73. http://dx.doi.org/10.1016/j.therap.2016.07.001.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

Gérardin, Marie, François Etcheverrigaray, Julien Nizard, et al. "Patients douloureux chroniques suivis dans un centre d’évaluation et de traitement de la douleur : quelles notifications en addictovigilance ?" Therapies 72, no. 1 (2017): 169. http://dx.doi.org/10.1016/j.therap.2016.11.052.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Mezaache, Salim, Franck Turlure, Nathalie Fredon, Joëlle Micallef, and Elisabeth Frauger. "Prévention des surdoses d’opioïdes et diffusion de naloxone : implication d’un CEIP-addictovigilance et illustration avec le projet POP." Therapies 77, no. 6 (2022): 761. http://dx.doi.org/10.1016/j.therap.2022.10.017.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

Daveluy, Amélie, Magali Labadie, Karine Titier, et al. "Poisoning by synthetic cathinones: Consumption behaviour and clinical description from 11 cases recorded by the Addictovigilance Centre of Bordeaux." Toxicologie Analytique et Clinique 29, no. 1 (2017): 34–40. http://dx.doi.org/10.1016/j.toxac.2016.11.005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Djezzar, S., F. Vorspan, D. Chataigner, E. Burin, R. Garnier, and J. P. Lépine. "Mephenesin dependence: A case series." European Psychiatry 26, S2 (2011): 29. http://dx.doi.org/10.1016/s0924-9338(11)71740-0.

Full text
Abstract:
IntroductionMephenesin is a central muscle relaxant, acting through a depression of the activity of some neurones in the caudate nucleus. It was proposed as a potential treatment of alcohol withdrawal syndrome in the 50s. This over the counter medicine is now mainly prescribed to treat spasticity or as an adjunctive treatment of painful muscle spasm. We know little about this substance except that side effects are venous thrombosis, haemolysis or cutaneous intolerance. Yet, no case of abuse or dependence has been reported.AimsTo report a series of 5 clinical cases in patients who developed abu
APA, Harvard, Vancouver, ISO, and other styles
32

Ponté, Camille. "Diagnostic de syndrome malin des neuroleptiques en contexte de consommation de substances dopaminergiques et sérotoninergiques ? Apport des données toxicologiques en Addictovigilance." Toxicologie Analytique et Clinique 32, no. 4 (2020): S51—S52. http://dx.doi.org/10.1016/j.toxac.2020.09.025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Le Boisselier, Reynald, Virginie Philippe, Céline Eiden, and Veronique Savignat. "Addictovigilance de la MDMA (ecstasy) en France : l’émergence de « nouvelles substances » ne doit pas éclipser le suivi sanitaire des plus anciennes." Therapies 77, no. 6 (2022): 757. http://dx.doi.org/10.1016/j.therap.2022.10.011.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Marillier, M., A. Batisse, C. Chevallier, L. Laviale, and S. Djezzar. "Cannabinoid hyperemesis syndrome: A Parisian case series." European Psychiatry 41, S1 (2017): s869—s870. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1745.

Full text
Abstract:
IntroductionCurrently, cannabis remains the most widely used illicit psychoactive substance in the world. Its main pharmacological properties are known and its use for therapeutic purpose is still expanding. Also, its acute and chronic toxicity become more described, even if some mechanisms of pharmacotoxicology still remain to clarify as the cannabinoid hyperemesis syndrome (CHS).ObjectivesTo describe cases of CHS, to highlight the clinical presentation and all the complexity of the medical exploration for making an accurate diagnosis.MethodWe present a case series of CHS related to cannabis
APA, Harvard, Vancouver, ISO, and other styles
35

Batisse, A., N. Taright, C. Chevallier, M. Marillier, and S. Djezzar. "“Dual disorder with drugs”: Comparison of two French databases." European Psychiatry 33, S1 (2016): S72. http://dx.doi.org/10.1016/j.eurpsy.2016.01.005.

Full text
Abstract:
ContextDual diagnosis (substance used disorders (SUD) and mental illness) represents 3% of general population. Among United States population, 42.3% of SUD patients have psychiatric troubles (without tobacco). Moreover, SUD can concern all psychoactive substances (PAS) or illicit PAS only named “dual disorder with drugs” (DDD).MethodsA quantitative analysis of DDD data from January 2013 to July 2014 of two epidemiological tools has been performed: PMSI database (Programme Médicalisé des Systeme d’Information) hospital discharge data is made up of data providing medical information for all pati
APA, Harvard, Vancouver, ISO, and other styles
36

Barrangou-Poueys-Darlas, Malcolm, Marie Gerardin, Sylvie Deheul, et al. "Poppers Use and High Methaemoglobinaemia: ‘Dangerous Liaisons’." Pharmaceuticals 14, no. 10 (2021): 1061. http://dx.doi.org/10.3390/ph14101061.

Full text
Abstract:
Poppers are legal and largely used in France despite severe side effects, such as methaemoglobinaemia (MetHbia). Our work aimed to assess the prevalence of poppers consumers among patients with a MetHbia higher than or equal to 5% in French university hospitals and its evolution before and after the legalization of poppers in France. We conducted a national multicentre observational retrospective study. All patients for whom at least one MetHbia measurement was performed from 2012 to 2017 in university hospitals where the French addictovigilance network (FAN) is implanted were included. For ea
APA, Harvard, Vancouver, ISO, and other styles
37

Batisse, A., C. Chevallier, J. Azevedo Correia, et al. "Example of alert and reporting system of scopolamine poisoning among Parisian cocaine users at regional, national and European levels." European Psychiatry 41, S1 (2017): s858. http://dx.doi.org/10.1016/j.eurpsy.2017.01.1709.

Full text
Abstract:
IntroductionIn the literature, few intoxications are related to scopolamine due to its presence in cocaine, heroin or even in counterfeit rohypnol tablets. Nonetheless, during summer 2016, several cases of non-fatal intoxication appeared in the region of Paris.ObjectivesDemonstrate how clinical detection of rare toxic events are fostered by exchanges in close collaboration with different territorial level.AimsImprove the detection of short toxic epidemic.MethodsSuspected cases of scopolamine poisoning notified to Parisian Addictovigilance centre were reported. Information shared through differ
APA, Harvard, Vancouver, ISO, and other styles
38

Gérardin, Marie, Morgane Rousselet, Pascal Caillet, et al. "French national health insurance database analysis and field study focusing on the impact of secure prescription pads on zolpidem consumption and sedative drug misuse: ZORRO study protocol." BMJ Open 9, no. 6 (2019): e027443. http://dx.doi.org/10.1136/bmjopen-2018-027443.

Full text
Abstract:
IntroductionIn recent years, data collected by the French Addictovigilance Network have shown the potential for abuse and addiction associated with zolpidem (the most sold hypnotic drug in France). Since 10 April 2017, new regulations have come into force that require zolpidem to be prescribed on special secure prescription pads, in order to reduce the risk of abuse or misuse. This measure has far-reaching repercussions that are not only limited to the consumption of zolpidem but also extend to the usage of sedative medication on a whole. The objective of the ZOlpidem and the Reinforcement of
APA, Harvard, Vancouver, ISO, and other styles
39

Lapeyre-Mestre, Maryse. "Addictovigilance in women, the hidden part of the iceberg?" Therapies, October 2022. http://dx.doi.org/10.1016/j.therap.2022.10.006.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Batisse, Anne, Céline Eiden, Sylvie Deheul, Emilie Monzon, Samira Djezzar, and Hélène Peyrière. "Chemsex practice in France: An update in Addictovigilance data." Fundamental & Clinical Pharmacology, September 14, 2021. http://dx.doi.org/10.1111/fcp.12725.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Guerlais, Marylène, Aurélie Aquizerate, Arthur Lionnet, et al. "Nitrous oxide: a unique official French addictovigilance national survey." Frontiers in Public Health 11 (May 3, 2023). http://dx.doi.org/10.3389/fpubh.2023.1167746.

Full text
Abstract:
IntroductionNitrous oxide has become over the last few years a public health problem in many countries. France has a dedicated health monitoring system dedicated to the surveillance of the abuse, dependence and consequences associated with the use of psychoactive substances coordinated by the French National Agency for the Safety of Medicines and Health Products.We present the French national survey of nitrous oxide.Materials and methodsWe analyzed all the cases with nitrous oxide from 2012 to 2021: number of notifications, characteristics of the subjects and consumption, consequences reported
APA, Harvard, Vancouver, ISO, and other styles
42

Tambon, Marine, Camille Ponté, Emilie Jouanjus, Nathalie Fouilhé, Joelle Micallef, and Maryse Lapeyre-Mestre. "Gabapentinoid Abuse in France: Evidence on Health Consequences and New Points of Vigilance." Frontiers in Psychiatry 12 (February 3, 2021). http://dx.doi.org/10.3389/fpsyt.2021.639780.

Full text
Abstract:
Introduction: Gabapentinoid drugs (gabapentin and pregabalin) are widely used worldwide for epileptic and pain disorders. First signals of gabapentinoid abuse occurred in the last decade. This study aims to describe clinical characteristics of gabapentinoid use related disorders and health consequences in France.Materials and Methods: We designed a multisource investigation reviewing data reported to the French Addictovigilance Network (FAN) with pregabalin and gabapentin from 2010 to 2019. Information was obtained through the analysis of Spontaneous Reports (SRs) notified by health profession
APA, Harvard, Vancouver, ISO, and other styles
43

"Erratum: Nitrous oxide: a unique official French addictovigilance national survey." Frontiers in Public Health 11 (July 4, 2023). http://dx.doi.org/10.3389/fpubh.2023.1235720.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Aquizerate, Aurélie, Edouard-Jules Laforgue, Marion Istvan, et al. "Evolution of the Addictovigilance Signal of Zopiclone: A 2014–2020 National Follow-up Study." International Journal of Mental Health and Addiction, May 31, 2023. http://dx.doi.org/10.1007/s11469-023-01078-y.

Full text
Abstract:
AbstractZopiclone, like zolpidem, is under surveillance in France due to its potential for dependence, abuse and misuse. However, part of the narcotics regulation was implemented in 2017 in France for zolpidem only, which has led to an increase in the number of zopiclone consumers. The objective of this article is to present French addictovigilance data regarding the evolution of the abuse, dependence and misuse profiles of zopiclone. We used the following 3 data sources over two periods: the 3-year period before the regulatory measure regarding zolpidem (2014–2016) and the 3-year period after
APA, Harvard, Vancouver, ISO, and other styles
45

Diaz, Laurine, Céline Eiden, Emilie Jouanjus, et al. "Alprazolam misuse: Analysis of French Addictovigilance Network data from 2011 to 2020." Therapies, February 2023. http://dx.doi.org/10.1016/j.therap.2023.02.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Eiden, Céline, Marc Vincent, Chris Serrand, et al. "Health consequences of cocaine use in France: data from the French Addictovigilance Network." Fundamental & Clinical Pharmacology, October 2, 2020. http://dx.doi.org/10.1111/fcp.12603.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Bouquet, Emilie, Stéphanie Pain, Céline Eiden, et al. "Adverse events of recreational cannabis use reported to the French addictovigilance network (2012–2017)." British Journal of Clinical Pharmacology, April 19, 2021. http://dx.doi.org/10.1111/bcp.14812.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Bouquet, Emilie, Céline Eiden, Bernard Fauconneau, et al. "Adverse events of recreational cannabis use during pregnancy reported to the French Addictovigilance Network between 2011 and 2020." Scientific Reports 12, no. 1 (2022). http://dx.doi.org/10.1038/s41598-022-19197-2.

Full text
Abstract:
AbstractCannabis is the main illicit psychoactive substance used by pregnant women in France. The aim of the present national survey was to describe adverse events (AEs) of recreational cannabis use during pregnancy reported to the French Addictovigilance Network (FAN). Spontaneous reports (SRs) of AEs related to recreational cannabis use during pregnancy were collected by the FAN between 01/01/2011 and 31/01/2021 (excluding cannabidiol and synthetic cannabinoids). Over the study period, 160 SRs involved cannabis use alone or in association with tobacco (59% of all SRs) which increased. Among
APA, Harvard, Vancouver, ISO, and other styles
49

Roussin, Anne, Thomas Soeiro, Charlotte Fouque, et al. "Increase of high‐risk tramadol use and harmful consequences in France from 2013 to 2018: Evidence from the triangulation of addictovigilance data." British Journal of Clinical Pharmacology, April 5, 2022. http://dx.doi.org/10.1111/bcp.15323.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Gandolfo, Pauline, Thomas Soeiro, Élisabeth Jouve, et al. "Patterns of ketamine use among people with substance use disorder in France: Multisource analysis of the data from the French Addictovigilance Network." Fundamental & Clinical Pharmacology, February 19, 2024. http://dx.doi.org/10.1111/fcp.12995.

Full text
Abstract:
AbstractBackgroundDue to its psychoactive effects, ketamine has become a drug used for non‐medical purpose.ObjectivesTo assess the latest trends in ketamine use among people with substance use disorder and to characterize its clinical complications using complementary health data sources of the French Addictovigilance Network.MethodsFirst, we extracted all reports involving ketamine from 2012 to 2021 from the database of the OPPIDUM program (i.e., a multicentric program conducted in collaboration with hundreds of substance abuse treatment facilities that collects data on drugs used by subjects
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!